<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dasatinib: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dasatinib: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dasatinib: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8852" href="/d/html/8852.html" rel="external">see "Dasatinib: Drug information"</a> and <a class="drug drug_patient" data-topicid="11617" href="/d/html/11617.html" rel="external">see "Dasatinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3020472"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sprycel</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868793"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Dasatinib;</li>
<li>REDDY-Dasatinib;</li>
<li>Sprycel;</li>
<li>TARO-Dasatinib;</li>
<li>TEVA-Dasatinib</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F5949966"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Tyrosine Kinase Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F50836850"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49c961bb-ce39-4a65-be68-00d42b082a27">Acute lymphoblastic leukemia, Philadelphia chromosome-positive, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL), Philadelphia chromosome-positive (Ph+), newly diagnosed: Note:</b> Use in combination with chemotherapy; dose escalation is not recommended; initiate dasatinib on or before day 15 of induction chemotherapy. Continue treatment for 2 years. Recalculate the dose every 3 months or as clinically necessary based on changes in body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children weighing ≥10 kg and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">10 to &lt;20 kg: 40 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;30 kg: 60 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">30 to &lt;45 kg: 70 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: 100 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4783761d-cf6d-45ed-a4b1-176fb0d5db43">Chronic myelogenous leukemia, Philadelphia chromosome-positive, chronic phase</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myelogenous leukemia (CML), Philadelphia chromosome-positive (Ph+), </b>
<b>chronic phase:</b>
<b>Note:</b> Continue dasatinib until disease progression or unacceptable toxicity. Recalculate the dose every 3 months or as clinically necessary based on changes in body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children weighing ≥10 kg and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">10 to &lt;20 kg: Initial: 40 mg once daily; may escalate to 50 mg once daily if hematologic or cytogenetic response is not achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;30 kg: Initial: 60 mg once daily; may escalate to 70 mg once daily if hematologic or cytogenetic response is not achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">30 to &lt;45 kg: Initial: 70 mg once daily; may escalate to 90 mg once daily if hematologic or cytogenetic response is not achieved.</p>
<p style="text-indent:-2em;margin-left:6em;">≥45 kg: Initial: 100 mg once daily; may escalate to 120 mg once daily if hematologic or cytogenetic response is not achieved.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity:</i> Children and Adolescents: Adjustments are specific for indications. <b>Note:</b> Growth factor support may be considered in patients with resistant myelosuppression.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Acute lymphoblastic leukemia, Philadelphia chromosome-positive (Ph+ ALL):</b> If neutropenia and/or thrombocytopenia result in a delay of the next block of treatment by &gt;14 days, interrupt dasatinib treatment and resume at the same level once the next block of treatment is started. If neutropenia and/or thrombocytopenia persist and the next block of treatment is delayed another 7 days, perform a bone marrow assessment to assess cellularity and blast percentage. If marrow cellularity is &lt;10%, interrupt dasatinib treatment until ANC &gt;500/mm<sup>3</sup> and then resume dasatinib at the full dose. If marrow cellularity is &gt;10%, consider resuming dasatinib.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Chronic myelogenous leukemia, Philadelphia chromosome-positive (Ph+ CML):</b></p>
<p style="text-indent:-2em;margin-left:8em;">If cytopenia (eg, neutropenia, thrombocytopenia) persists for &gt;3 weeks, determine if cytopenia is due to leukemia by performing a marrow aspirate or biopsy.</p>
<p style="text-indent:-2em;margin-left:8em;">If cytopenia is unrelated to leukemia, withhold dasatinib until ANC ≥1,000/mm<sup>3</sup> and platelets ≥75,000/mm<sup>3</sup> and resume dasatinib at the original starting dose or at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If cytopenia recurs, repeat marrow aspirate/biopsy and resume dasatinib at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>If ≥ grade 3 neutropenia or thrombocytopenia recurs during complete hematologic response, interrupt dasatinib therapy and resume at a reduced dose. Temporary dose reductions for intermediate degrees of cytopenia and disease response may be used as needed.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Recommended dose reductions for neutropenia and thrombocytopenia in Ph+ CML:</i></p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 40 mg daily, may reduce dose to 20 mg once daily (one-level dose reduction); further dose reductions cannot be made due to available tablet sizes.</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 60 mg once daily, may reduce dose to 40 mg once daily (one-level dose reduction), and then to 20 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 70 mg once daily, may reduce dose to 60 mg once daily (one-level dose reduction), and then to 50 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 100 mg once daily, may reduce dose to 80 mg once daily (one-level dose reduction), and then to 70 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonhematologic toxicity: </i>Recommendations exclude altered liver enzymes (see Dosing: Hepatic Impairment: Pediatric).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Ph+ ALL:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Grade 2 toxicity: If no recovery despite symptomatic management, consider interrupting dasatinib therapy; once recovered to ≤ grade 1, resume at the original starting dose. For recurrent events, resume dasatinib at a reduced dose (see the following dose reductions).</p>
<p style="text-indent:-2em;margin-left:8em;">Grade ≥3 toxicity: Withhold dasatinib until recovered to grade 1 or lower, and then resume at a reduced dose (see the following dose reductions).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Recommended dose reductions for non-hematologic toxicities Ph+ ALL:</i></p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 40 mg daily, may reduce dose to 20 mg once daily (one-level dose reduction); further dose reductions cannot be made due to available tablet sizes.</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 60 mg once daily, may reduce dose to 40 mg once daily (one-level dose reduction), and then to 20 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 70 mg once daily, may reduce dose to 60 mg once daily (one-level dose reduction), and then to 50 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 100 mg once daily, may reduce dose to 80 mg once daily (one-level dose reduction), and then to 70 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Ph+ CML:</i></b>
<i>Severe nonhematologic toxicity: </i>Withhold treatment until toxicity improvement or resolution; if appropriate, resume treatment at a reduced dose based on the event severity and recurrence.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>All indications:</i></b>
<i> Management of other nonhematologic toxicities:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dermatologic toxicities</i>: Manage rash with antihistamines or topical or systemic steroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19195046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19195046'])">Ref</a></span>), or treatment interruption, dose reduction, or discontinuation. Discontinue if dasatinib-related severe mucocutaneous reaction occurs.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Fluid retention:</i> Manage with diuretics, short courses of corticosteroids, and/or supportive care. Severe pleural effusions may require thoracentesis and oxygen therapy; consider dose reduction or treatment interruption.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Pleural effusion:</i> For first episode of grade 3 pleural effusion, withhold treatment until resolves to grade 1 or lower and consider corticosteroids (eg, prednisone for 3 to 4 days), diuretics, thoracentesis, and/or pleurodesis; may resume dasatinib at a decreased dose (one-level dose reduction) when effusion resolves; if pleural effusion recurs, initiate supportive therapy, withhold therapy, and resume at next lower dose level (two-level dose reduction) or discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19195046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19195046'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Pulmonary arterial hypertension:</i> Discontinue with confirmed pulmonary arterial hypertension.</p></div>
<div class="block dorp drugH1Div" id="F51108763"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, &lt;4% of dasatinib and metabolites are renally excreted.</p></div>
<div class="block dohp drugH1Div" id="F51108764"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline (prior to therapy initiation):</i> No initial dosage adjustment is necessary; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatic impairment during therapy: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ph+ ALL: </b></p>
<p style="text-indent:-2em;margin-left:8em;">If direct bilirubin &gt;5 times ULN or ALT/AST &gt;15 times ULN, first episode: Hold dasatinib; once recovered to ≤ grade 1, resume therapy at the original starting dose.</p>
<p style="text-indent:-2em;margin-left:8em;">If direct bilirubin &gt;5 times ULN or ALT/AST &gt;15 times ULN recur, reduce dasatinib dose based on the following:</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 40 mg daily, may reduce dose to 20 mg once daily (one-level dose reduction); further dose reductions cannot be made due to available tablet sizes.</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 60 mg once daily, may reduce dose to 40 mg once daily (one-level dose reduction), and then to 20 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 70 mg once daily, may reduce dose to 60 mg once daily (one-level dose reduction), and then to 50 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:10em;">If the original starting dose is 100 mg once daily, may reduce dose to 80 mg once daily (one-level dose reduction), and then to 70 mg once daily (two-level dose reduction).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ph+ CML: </b>Transaminase or bilirubin elevations during treatment may be managed with treatment interruption or dose reduction.</p></div>
<div class="block doa drugH1Div" id="F3020532"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8852" href="/d/html/8852.html" rel="external">see "Dasatinib: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The effect of discontinuation on long-term disease outcome after achieving cytogenetic response (including complete cytogenetic response) or major molecular response is not known. Use with caution in patients where fluid accumulation may be poorly tolerated, such as in cardiovascular disease (heart failure or hypertension) and pulmonary disease. Correct hypokalemia and hypomagnesemia prior to and during dasatinib therapy. Maintain adequate hydration and correct uric acid levels prior to treatment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88b25fc8-fc64-44d0-9a5e-582559ccf648">Acute lymphoblastic leukemia, Philadelphia chromosome-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, Philadelphia chromosome-positive (Ph+): </b>
<b>Oral:</b> 140 mg once daily until disease progression or unacceptable toxicity occurs. Consider a dose escalation to 180 mg once daily in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing/combinations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dasatinib in combination with low-intensity chemotherapy; EWALL-PH-01 </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27121472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27121472'])">Ref</a></span>): Patients ≥55 years of age: <b>Oral:</b> 140 mg once daily (100 mg once daily if ≥70 years) for 6 weeks during the induction period, followed by 100 mg once daily discontinuously during consolidation and maintenance, followed by postmaintenance of 100 mg once daily until relapse; dasatinib was administered in combination with chemotherapy; refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dasatinib in combination with Hyper-</i>
<i>CVAD </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29046900']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29046900'])">Ref</a></span>): Patients ≤60 years of age: <b>Oral:</b> 100 mg once daily for the first 14 days of the first Hyper-CVAD (high-intensity chemotherapy) cycle, followed by 70 mg once daily continuously during Hyper-CVAD cycles 2 through 8, followed by maintenance therapy with dasatinib 100 mg once daily (in combination with vincristine and prednisone) for 2 years, and then dasatinib was continued indefinitely thereafter. Patients who underwent hematopoietic cell transplant received dasatinib 100 mg once daily beginning on day 100 posttransplant and continued for up to 5 years. Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dasatinib in combination with chemotherapy </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26951627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26951627'])">Ref</a></span>): Patients ≤65 years of age: <b>Oral:</b> 100 mg once daily for 4 weeks of each cycle for up to 4 cycles; for each cycle, chemotherapy was initiated first, followed by 4 weeks of dasatinib beginning when blood counts had recovered. Dasatinib was administered in combination with chemotherapy; refer to protocol for further information. Patients with a stem cell donor could receive up to 4 cycles total, followed by allogeneic stem cell transplant as early as possible. Patients unable to proceed to transplant could receive up to 4 cycles total, followed by dasatinib maintenance of 100 mg once daily for 2 years.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Protocol LAL1205</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21931113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21931113'])">Ref</a></span>): <b>Oral:</b> Induction therapy: 70 mg twice daily for 84 days (in combination with prednisone and intrathecal methotrexate). <b>Note: </b>Patients received a 7-day steroid prephase prior to induction therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>GIMEMA LAL2116 </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33085860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33085860'])">Ref</a></span>): <b>Oral:</b> 140 mg once daily for 85 days in combination with glucocorticoid (induction therapy), followed by postinduction consolidation treatment with dasatinib 140 mg once daily in combination with blinatumomab. Therapy was continued for a minimum of 2 cycles; up to 3 additional cycles were allowed. <b>Note: </b>Patients received a 7-day steroid prephase prior to induction therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0632ab14-f4fd-49b6-93a6-477819ae42e6">Chronic myeloid leukemia, Philadelphia chromosome-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia (CML), Philadelphia chromosome-positive:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32734668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32734668'])">Ref</a></span>)<i>: </i>A British Society for Haematology guideline on the diagnosis and management of CML recommends considering a second-generation tyrosine kinase inhibitor (TKI) such as dasatinib as initial therapy for newly diagnosed chronic phase CML in patients with a high or intermediate EUTOS long-term survival (ELTS) or Sokal score; assess comorbidities and TKI toxicity profile to determine the appropriate TKI. An alternative TKI should be considered if treatment failure on first-line therapy occurs; the choice of second-line therapy should be guided by BCR-ABL mutational analysis as well as patient- and drug-specific characteristics. Patients with de novo accelerated phase CML should ideally be managed with a second generation TKI. Some patients may be candidates for a treatment-free remission (TFR); specific criteria and monitoring parameters must be met in order to discontinue treatment; refer to guideline for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CML, Ph+, newly diagnosed in chronic phase: </b>
<b>Oral:</b> 100 mg once daily until disease progression or unacceptable toxicity occurs. Consider a dose escalation to 140 mg once daily in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CML, Ph+, resistant or intolerant:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chronic phase:</i>
<b>Oral: </b>100 mg once daily until disease progression or unacceptable toxicity occurs. Consider a dose escalation to 140 mg once daily in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Accelerated or blast phase:</i>
<b>Oral: </b>140 mg once daily until disease progression or unacceptable toxicity occurs. Consider a dose escalation to 180 mg once daily in patients not achieving hematologic or cytogenetic response at recommended initial dosage.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68f8df71-9028-41a5-9040-b8077357fe37">Gastrointestinal stromal tumor, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumor (GIST), advanced (off-label use): </b>
<b>Oral:</b> 70 mg twice daily until disease progression or unacceptable toxicity; refer to protocols for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29315500','lexi-content-ref-29710216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29315500','lexi-content-ref-29710216'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, take the next regularly scheduled dose; 2 doses should not be taken at the same time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991828"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: No need for dosage adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989112"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Altered hepatic function at treatment initiation</i>
<i>:</i> No initial dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment</i>
<i>:</i> Transaminase or bilirubin elevations during treatment may be managed with treatment interruption, dose reduction, or permanent discontinuation.</p></div>
<div class="block adr drugH1Div" id="F3020507"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (12%), skin rash (11% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention (19% to 48%; cardiac-related: 9%), hypocalcemia (grades 3/4: ≤12%), hypokalemia (grades 3/4: 2% to 15%), hypophosphatemia (grades 3/4: 7% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7% to 16%), diarrhea ( 17% to 31%; grades 3/4: ≤5%), nausea (8% to 24%; grades 3/4: 1% to 3%), vomiting (5% to 16%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (grades 3/4: 13% to 74%), febrile neutropenia (4% to 12%; grades 3/4: 4% to 12%), hemorrhage (8% to 26%; grades 3/4: 1% to 9%), neutropenia (grades 3/4: 29% to 79%), thrombocytopenia (grades 3/4: 22% to 85%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (9% to 14%; serious infection: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized edema (3% to 22%; superficial)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (8% to 26%), headache (12% to 33%), pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5% to 13%), limb pain (19%), musculoskeletal pain (8% to 22%), myalgia (7% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3% to 24%), pleural effusion (10% to 28%; serious: 5% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac conduction disturbance (7%; including cardiac arrhythmias [tachycardia, ventricular arrhythmia, ventricular tachycardia] and palpitations), cardiac disorder (≤4%; including cardiomyopathy, heart failure, left ventricular dysfunction, ischemic heart disease, reduced ejection fraction), chest pain, edema (1% to 4%), flushing, hypertension, pericardial effusion (1% to 4%), prolonged QT interval on ECG (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, dermatitis, eczema, hyperhidrosis, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, change in appetite, colitis (including neutropenic colitis), constipation (10%), dysgeusia, dyspepsia, enterocolitis, gastritis, gastrointestinal hemorrhage (2% to 9%), stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (grades 3/4: ≤5%), increased serum aspartate aminotransferase (grades 3/4: ≤4%), increased serum bilirubin (grades 3/4: ≤6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, chills, depression, dizziness, drowsiness, insomnia, intracranial hemorrhage (≤3%), myasthenia, neuropathy, peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Abnormal bone growth (children: 5%; including epiphyses delayed fusion, growth suppression, osteopenia), muscle spasm (5%), stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, decreased visual acuity, dry eye syndrome, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (grades 3/4: 1% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, pneumonia, pneumonitis, pulmonary edema (≤4%), pulmonary hypertension (1% to 5%), pulmonary infiltrates, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Soft tissue injury (oral)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal T waves on ECG, acute coronary syndrome, angina pectoris, cardiomegaly, coronary artery disease, deep vein thrombosis, embolism, hypotension, livedo reticularis, myocarditis, pericarditis, pleuropericarditis, prolongation P-R interval on ECG, pulmonary embolism, syncope, thrombophlebitis, thrombosis, troponin increased in blood specimen</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous skin disease, dermal ulcer, dyschromia, erythema nodosum, hair disease, nail disease, palmar-plantar erythrodysesthesia, skin photosensitivity, Sweet syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, dehydration, diabetes mellitus, gynecomastia, hypercholesterolemia, hyperthyroidism, hypoalbuminemia, hypothyroidism, menstrual disease, thyroiditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anal fissure, cholecystitis, cholestasis, dysphagia, esophagitis, gastroesophageal reflux disease, gastrointestinal disease (protein wasting), intestinal obstruction, pancreatitis (including acute pancreatitis), rectal fistula, upper gastrointestinal tract ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy, lymphocytopenia, pure red cell aplasia, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites, hepatitis, increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, amnesia, anxiety, ataxia, balance impairment, Bell palsy, cerebrovascular accident, confusion, dementia, emotional lability, malaise, seizure, transient ischemic attacks, tremor, vertigo, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, increased creatine phosphokinase in blood specimen, myositis, osteonecrosis, panniculitis, rhabdomyolysis, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, increased lacrimation, optic neuritis, photophobia, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Otic; Hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, asthma, bronchospasm, cor pulmonale</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fibrosis (dermal)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, atrial flutter</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic microangiopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease</p></div>
<div class="block coi drugH1Div" id="F3020503"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to dasatinib or any other component of the formulation; breast-feeding</p></div>
<div class="block war drugH1Div" id="F3020504"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Severe dose-related bone marrow suppression (thrombocytopenia, neutropenia, anemia) is associated with dasatinib. Hematologic toxicity is usually reversible with dosage adjustment and/or temporary treatment interruption. The incidence of myelosuppression is higher in patients with advanced phases of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular adverse events: Dasatinib may cause cardiac dysfunction; cardiac ischemic events, cardiac fluid retention-related events, and conduction abnormalities (arrhythmia and palpitations) have been reported. Cases of transient ischemic attacks have been reported with dasatinib; there have also been cases of peripheral arterial occlusive disease with another BCR-ABL tyrosine kinase inhibitor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Cases of severe mucocutaneous dermatologic reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported with dasatinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention: Dasatinib may cause fluid retention, including pleural and pericardial effusions, pulmonary hypertension, and generalized or superficial edema. A prompt chest x-ray (or other appropriate diagnostic imaging) is recommended for symptoms suggestive of effusion (new or worsening dyspnea on exertion or at rest, pleuritic chest pain, or dry cough). Utilizing once-daily dosing has been associated with a decreased frequency of fluid retention; the risk for pleural effusion was increased in patients with hypertension, prior cardiac history and a twice a day administration schedule (Quintás-Cardama 2007). Grade 3 or 4 fluid retention/pleural effusion was observed in adults and grade 1 or 2 fluid retention was observed in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Dasatinib may cause serious and fatal bleeding, including grades 3 and higher CNS hemorrhage. The most frequent hemorrhage site was GI. Grades 3 or 4 hemorrhage usually required treatment interruptions and transfusions. Most bleeding events in clinical studies were associated with severe thrombocytopenia, although dasatinib may also cause platelet dysfunction. Concomitant medications that inhibit platelet function or anticoagulants may increase the risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Dasatinib may cause hepatotoxicity (eg, increased bilirubin, AST, ALT, alkaline phosphatase). Transaminase elevation and hyperbilirubinemia have been observed when dasatinib was administered in combination with chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary arterial hypertension: Dasatinib may increase the risk for pulmonary arterial hypertension (PAH) in both adult and pediatric patients. PAH may occur at any time after starting treatment, including after &gt;12 months of therapy; may be reversible following dasatinib discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Dasatinib may increase the risk for QT interval prolongation; there are rare reports of patients with QTcF &gt;500 msec. The risk for QT prolongation is increased in patients with long QT syndrome, patients taking antiarrhythmic medications or other medications that lead to QT prolongation or potassium-wasting diuretics, patients with cumulative high-dose anthracycline therapy, and conditions which cause hypokalemia or hypomagnesemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS) has been reported in patients with resistance to prior imatinib therapy, usually in patients with advanced phase disease. Risk for TLS is higher in patients with advanced stage disease and/or a high tumor burden.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drugs that affect gastric pH: Elevated gastric pH may reduce dasatinib bioavailability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age are more likely to experience toxicity (compared with patients &lt;65 years of age).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Adverse reactions associated with bone growth and development have been reported in pediatric studies of chronic phase CML (including a report of severe [grade 3] growth retardation). Cases have included epiphyses delayed fusion, osteopenia, growth retardation, and gynecomastia; some cases resolved during treatment.</p></div>
<div class="block prod-avail drugH1Div" id="F58912427"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Phyrago tablets: FDA approved December 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Phyrago is indicated for the treatment of adult patients with of newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase or treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib or Ph+ ALL with resistance or intolerance to prior therapy. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F3020543"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sprycel: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg</p></div>
<div class="block geq drugH1Div" id="F3020474"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322945"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sprycel Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $202.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $404.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $404.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $729.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $729.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">140 mg (per each): $729.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868794"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sprycel: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg</p></div>
<div class="block exp drugH1Div" id="F12807008"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">An oral suspension may be prepared by dissolving dasatinib tablet(s) for one dose in 30 mL chilled orange or apple juice (without preservatives). After 5 minutes, swirl the contents for 3 seconds and repeat the process every 5 minutes for a total of 20 minutes following addition of tablet(s). Minimize time between end of 20 minutes and administration since suspension will taste more bitter if allowed to stand longer. Swirl contents of container one last time, then administer immediately. To ensure the full dose is administered, rinse container with 15 mL juice and administer residue. May be administered orally (or by nasogastric tube). Discard any unused portion after 60 minutes.</p>
<div class="reference">Sprycel data on file, Bristol-Myers Squibb</div>
</div>
<div class="block admp drugH1Div" id="F52614208"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer once daily (morning or evening). May be taken without regard to food. Swallow whole; do not break, crush, or chew tablets. Take with a meal if GI upset occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19195046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19195046'])">Ref</a></span>). Do not administer proton pump inhibitors and H<sub>2</sub> blockers concomitantly with dasatinib. If needed, may consider antacid administration, separated by at least 2 hours before or 2 hours after the dasatinib dose. <b>Note:</b> Crushing and dispersing a tablet in juice showed decreased exposure to dasatinib (36% lower) in pediatric patients (n=5, age range: 2 to 10 years); safety and efficacy of this administration method are undetermined; an extemporaneous suspension can be prepared (see Extemporaneous Preparations).</p></div>
<div class="block adm drugH1Div" id="F3020536"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer either in the morning or the evening (for once-daily dosing); has also been administered twice daily (in off-label uses). Swallow whole; do not break, cut, crush, or chew tablets. Administer with or without meals. Administer with a meal if GI upset occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19195046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19195046'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49130978"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F3020520"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;text-align:justify;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53570061"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy (FDA approved in pediatric patients ≥1 year); treatment of chronic phase Ph+ chronic myeloid leukemia (Ph+ CML) (FDA approved in pediatric patients ≥1 year); treatment of Ph+ ALL with resistance or intolerance to prior therapy (FDA approved in adults); treatment of newly diagnosed Ph+ CML in chronic phase (FDA approved in adults); treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F3401602"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dasatinib may be confused with asciminib, bosutinib, cabozantinib, dabrafenib, dacomitinib, duvelisib, enasidenib, fedratinib, imatinib, lapatinib, neratinib, nilotinib, pacritinib, PONATinib, SUNItinib, tucatinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F3020515"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F3020514"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen. Management: Avoid coadministration of acetaminophen and dasatinib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Dasatinib may enhance the anticoagulant effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Dasatinib. Management: Simultaneous administration of dasatinib and antacids should be avoided. Administer antacids 2 hours before or 2 hours after dasatinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Dasatinib may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May increase the serum concentration of Dasatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Dasatinib. Management: Avoid concurrent use of dasatinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Dasatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dasatinib. Management: This combination should be avoided if possible. If combined, decrease dasatinib dose from 140 mg to 40 mg, 100 mg to 20 mg, or 70 mg to 20 mg. For patients taking 60 mg or 40 mg daily, stop dasatinib until the CYP3A4 inhibitor is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Dasatinib. Encorafenib may decrease the serum concentration of Dasatinib. Management: Consider alternatives to this drug combination. If combined, consider increasing the dasatinib dose and monitor clinical response and toxicity. Additionally, monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Dasatinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the absorption of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Dasatinib. Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of PPIs or PCABs if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of PAZOPanib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Dasatinib may enhance the hepatotoxic effect of Propacetamol. Dasatinib may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, acetaminophen concentrations may increase.  Management: Consider less frequent or lower daily doses of propacetamol in patients taking dasatinib. Patients receiving dasatinib and propacetamol concomitantly, particularly those with greater propacetamol exposure, should be monitored for hepatotoxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Dasatinib. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of other QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Kinase Inhibitors (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Dasatinib. QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Dasatinib. Management: Avoid this combination if possible. If combined, decrease dasatinib dose from 140 mg to 40 mg, 100 mg to 20 mg, or 70 mg to 20 mg. If taking 60 mg or 40 mg daily, stop dasatinib until the CYP3A4 inhibitor is discontinued. Monitor for prolonged QT interval<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Dasatinib may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Dasatinib.  Management: Avoid this combination if possible. If combined, decrease dasatinib dose from 140 mg to 40 mg, 100 mg to 20 mg, or 70 mg to 20 mg. If taking 60 mg or 40 mg daily, stop dasatinib until the CYP3A4 inhibitor is discontinued. Monitor for prolonged QT interval<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: QT-prolonging Kinase Inhibitors (Moderate Risk) may enhance the QTc-prolonging effect of RisperiDONE.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Dasatinib may enhance the QTc-prolonging effect of Saquinavir. Saquinavir may increase the serum concentration of Dasatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Dasatinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F3020518"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Dasatinib serum concentrations may be increased when taken with grapefruit or grapefruit juice. Management: Avoid concurrent use.</p></div>
<div class="block dic drugH1Div" id="F3020535"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Avoid grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F49297797"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant or who could father a child should use effective contraception during treatment and for 30 days after the last dasatinib dose.</p>
<p style="text-indent:0em;margin-top:2em;">Changes in menstrual patterns have been reported with tyrosine kinase inhibitor (TKI) therapy (Yu 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, TKIs have the potential to adversely affect fertility by acting on receptors in the ovaries or testis, primarily when administered prior to puberty in males. Although there are cases showing difficulty conceiving, successful pregnancies have also been reported. Fertility data related to long-term TKI use are limited. Recommendations are available for fertility preservation prior to TKI treatment (ASCO [Oktay 2018]; Madabhavi 2019; Rambhatla 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Patients planning to become pregnant but currently receiving a TKI should minimize the risk of first-trimester exposure (Rambhatla 2021). Discontinuing TKI therapy for chronic myeloid leukemia (CML) can be considered if the patient is eligible for a tumor-free remission, allowing a washout period before attempting to conceive (Baccarani 2019; ELN [Hochhaus 2020]; Madabhavi 2019). Because the time to conception can be highly variable, treatment may also be discontinued at the first positive pregnancy test, prior to organogenesis in select patients (Abruzzese 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following male use of dasatinib prior to conception are available (Cortes 2015; Rambhatla 2021; Szakács 2020). Based on available data, dasatinib does not need to be stopped prior to conception in patients diagnosed with CML planning to father a child (Abruzzese 2020; Baccarani 2019; BSH [Smith 2020]; ELN [Hochhaus 2020]).</p></div>
<div class="block pri drugH1Div" id="F5520659"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dasatinib crosses the placenta, with fetal plasma and amniotic concentrations comparable to maternal concentrations (Berveiller 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following use of dasatinib for the treatment of chronic myeloid leukemia (CML) or of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) during pregnancy are available (Assi 2021; Barkoulas 2018; Cortes 2015; Hermel 2019). Adverse effects, including hydrops fetalis and fetal leukopenia and thrombocytopenia have been reported following in utero exposure to dasatinib (Berveiller 2012; Cortes 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Persons who are pregnant are advised to avoid exposure to crushed or broken tablets.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of CML in pregnant patients should be individualized based on gestational age, hematologic parameters, and clinical condition at presentation. If pregnancy is detected in the first trimester in patients already on a tyrosine kinase inhibitor (TKI), treatment should be discontinued as soon as pregnancy is confirmed. Treatments other than a TKI are recommended in pregnant patients not eligible for a tumor-free remission. If a TKI is needed, use of dasatinib is not recommended (Abruzzese 2020; BSH [Smith 2020]; ELN [Hochhaus 2020]; Madabhavi 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53570062"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential:</p>
<p style="text-indent:-2em;margin-left:4em;">ALL, newly diagnosed: Baseline, prior to initiation of each block of chemotherapy, and then as clinically indicated and every 2 days until recovery during consolidation blocks of chemotherapy</p>
<p style="text-indent:-2em;margin-left:4em;">CML chronic phase: Every 2 weeks for 12 weeks and then every 3 months thereafter or as clinically indicated</p>
<p style="text-indent:-2em;margin-left:4em;">ALL accelerated or blast phase CML: Weekly for 2 months, then monthly or as clinically necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Bone marrow biopsy; liver function tests, electrolytes including calcium, phosphorus, magnesium; monitor for fluid retention; monitor for signs/symptoms of cardiac dysfunction; ECG monitoring if at risk for QTc prolongation; chest x-ray is recommended for symptoms suggestive of pleural effusion (eg, cough, dyspnea); signs/symptoms of tumor lysis syndrome and dermatologic reactions. Monitor bone growth/development in pediatric patients. Monitor blood pressure routinely (Armenian 2017). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid function testing recommendations (Hamnvik 2011):</p>
<p style="text-indent:-2em;margin-left:4em;">Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months</p>
<p style="text-indent:-2em;margin-left:4em;">Without preexisting thyroid hormone replacement: TSH at baseline, then monthly for 4 months, then every 2 to 3 months</p></div>
<div class="block pha drugH1Div" id="F3020521"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dasatinib is a BCR-ABL tyrosine kinase inhibitor that targets most imatinib-resistant BCR-ABL mutations (except the T315I and F317V mutants) by distinctly binding to active and inactive ABL-kinase. Kinase inhibition halts proliferation of leukemia cells. It also inhibits SRC family (including SRC, LKC, YES, FYN); c-KIT, EPHA2 and platelet derived growth factor receptor (PDGFRβ).</p></div>
<div class="block phk drugH1Div" id="F3020523"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 2,505 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Dasatinib: ~96%; metabolite (active): 93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: The adjusted geometric mean ratio was 0.84 for AUC in healthy adults who received tablets dispersed in juice (compared with intact tablets).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensive); metabolized by CYP3A4 (primarily), flavin-containing mono-oxygenase-3 (FOM-3) and uridine diphosphate-glucuronosyltransferase (UGT) to an active metabolite and other inactive metabolites (the active metabolite plays only a minor role in the pharmacology of dasatinib).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 3 to 5 hours (adults); 2 to 5 hours (pediatrics).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 0.5 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~85%, 19% as unchanged drug); urine (~4%, 0.1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 363.8 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51220922"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with moderate hepatic impairment (Child-Pugh class B) had decreases in mean C<sub>max</sub> and AUC by 47% and 8%, respectively, compared to subjects with normal hepatic function. Patients with severe hepatic impairment (Child-Pugh class C) had decreases in mean C<sub>max</sub> and AUC of 43% and 28%, respectively, compared with healthy controls.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539976"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dapibus | Dasan | Dasanova | Dasatinib gp pharm | Dasatixane | Dasonib | Dasterib | Drimof | Fontrax | Froxal | Leunib | Liteda | Rembre | Sprytinib | Ultracell | Zaltag</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib g.l. | Dasatinib hcs | Dasatinib sandoz | Sprycel</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib arx | Dasatinib dr. reddy's | Dasatinib sun | Sprycel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Mabic</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib mylan | Dasatinib teva | Sprycel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ladizac | Sprycel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Yi ni shu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dasinib | Etersa | Liteda | Rembre | Sprycel</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib mylan | Dasatinib teva | Sprycel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Daruph | Dasatilen | Dasatinib 1a pharma | Dasatinib AL | Dasatinib heumann | Dasatinib hexal | Dasatinib mylan | Dasatinib tillomed | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Etersa | Liteda</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dasalem | Dasatinib | Dasmiba | Etersa | Liteda</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib norameda | Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib mylan | Dasatinib stada | Dasatinib teva | Sprycel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Dasatinib mylan | Dasatinib sandoz | Dasatinib stada | Sprycel</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib biogaran | Dasatinib eg | Dasatinib krka | Dasatinib mylan | Dasatinib sandoz | Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib | Sprycel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Dasatinib onkogen | Dasatinib teva | Dasatinib zentiva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib clonmel | Sprycel</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alsatinib | Beedan | Dasacad | Dasafav | Dasamyl | Dasanat | Dasatib | Dasatrue | Daslemia | Dastila | Dyronib | Invista | Nextki | Spnib | Sprycel</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib eg | Dasatinib mylan | Dasatinib sandoz | Dasatinib zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Elpida | Sprycel</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib jg | Dasatinib nk | Dasatinib sawai | Dasatinib towa | Sprycel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib norameda | Dasatinib teva | Sprycel</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib mylan | Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib CF | Dasatinib sandoz | Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib sandoz | Dasatinib teva | Sprycel</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Atenib | Dasaphil | Leunib | Liteda | Sprycel</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Dasatinib mylan | Dasatinib sandoz | Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib vmg | Dasinib | Fontrax | Liteda | Rembre</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Daleubin | Sprycel</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Dasatinib pharos | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib nativ | Sprycel</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib spc | Elpida | Otrasa | Sprycel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Dasatinib mylan | Dasatinib sandoz | Dasatinib stada | Dasatinib teva | Dasatinib zentiva | Sprycel</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Sprycel</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib krka | Dasatinib teva | Dasatinib zentiva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib neapolis | Sprycel | Theracell</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Sprycel | Sprytinib</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sprycel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dasatinib teva | Fylibix | Sprycel</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33194164">
<a name="33194164"></a>Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. <i>Ther Adv Hematol</i>. 2020;11:2040620720966120. doi:10.1177/2040620720966120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/33194164/pubmed" id="33194164" target="_blank">33194164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19487385">
<a name="19487385"></a>Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. <i>J Clin Oncol</i>. 2009;27(21):3472-3479.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/19487385/pubmed" id="19487385" target="_blank">19487385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33283580">
<a name="33283580"></a>Assi R, Kantarjian H, Keating M, et al. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience. <i>Leuk Lymphoma</i>. 2021;62(4):909-917. doi:10.1080/10428194.2020.1849672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/33283580/pubmed" id="33283580" target="_blank">33283580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31869412">
<a name="31869412"></a>Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Adv</i>. 2019;3(24):4280-4290. doi:10.1182/bloodadvances.2019000865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/31869412/pubmed" id="31869412" target="_blank">31869412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29284357">
<a name="29284357"></a>Barkoulas T, Hall PD. Experience with dasatinib and nilotinib use in pregnancy. <i>J Oncol Pharm Pract</i>. 2018;24(2):121-128. doi:10.1177/1078155217692399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/29284357/pubmed" id="29284357" target="_blank">29284357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22421368">
<a name="22421368"></a>Berveiller P, Andreoli A, Mir O, et al. A dramatic fetal outcome following transplacental transfer of dasatinib. <i>Anticancer Drugs</i>. 2012;23(7):754-757. doi:10.1097/CAD.0b013e328352a8fe<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/22421368/pubmed" id="22421368" target="_blank">22421368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22244674">
<a name="22244674"></a>Cornelison M, Jabbour EJ, Welch MA. Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner. <i>J Support Oncol</i>. 2012;10(1):14-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/22244674/pubmed" id="22244674" target="_blank">22244674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26348106">
<a name="26348106"></a>Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. <i>Am J Hematol</i>. 2015;90(12):1111-1115. doi:10.1002/ajh.24186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/26348106/pubmed" id="26348106" target="_blank">26348106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185463">
<a name="17185463"></a>Cortes J, Rousselot P, Kim DW, et al. Dasatinib Induces Complete Hematologic and Cytogenetic Responses in Patients With Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis. <i>Blood</i>. 2007;109(8):3207-3213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/17185463/pubmed" id="17185463" target="_blank">17185463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33085860">
<a name="33085860"></a>Foà R, Bassan R, Vitale A, et al; GIMEMA Investigators. Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults. <i>N Engl J Med</i>. 2020;383(17):1613-1623. doi:10.1056/NEJMoa2016272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/33085860/pubmed" id="33085860" target="_blank">33085860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21931113">
<a name="21931113"></a>Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i>. 2011;118(25):6521-6528. doi:10.1182/blood-2011-05-351403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/21931113/pubmed" id="21931113" target="_blank">21931113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17264298">
<a name="17264298"></a>Guilhot F, Apperley J, Kim DW, et al. Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients With Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia in Accelerated Phase. <i>Blood</i>. 2007;109(10):4143-4150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/17264298/pubmed" id="17264298" target="_blank">17264298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, Marqusee E. Thyroid Dysfunction From Antineoplastic Agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29207935">
<a name="29207935"></a>Hermel DJ, Chiu V, Hermel MH, Tulpule A, Akhtari M. Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib. <i>J Oncol Pharm Pract</i>. 2019;25(3):699-702. doi:10.1177/1078155217745710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/29207935/pubmed" id="29207935" target="_blank">29207935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32127639">
<a name="32127639"></a>Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. <i>Leukemia</i>. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/32127639/pubmed" id="32127639" target="_blank">32127639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138817">
<a name="17138817"></a>Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib Induces Notable Hematologic and Cytogenetic Responses in Chronic-Phase Chronic Myeloid Leukemia After Failure of Imatinib Therapy. <i>Blood</i>. 2007;109(6):2303-2309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/17138817/pubmed" id="17138817" target="_blank">17138817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19369231">
<a name="19369231"></a>Kantarjian H, Cortes J, Kim DW, et al. Phase 3 Study of Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients With Chronic Myeloid Leukemia in Accelerated Phase Resistant or Intolerant to Imatinib: 15-Month Median Follow-up. <i>Blood</i>. 2009;113(25):6322-639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/19369231/pubmed" id="19369231" target="_blank">19369231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22160483">
<a name="22160483"></a>Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: 2-year Follow-up From a Randomized Phase 3 Trial (DASISION). <i>Blood</i>. 2012;119(5):1123-1129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/22160483/pubmed" id="22160483" target="_blank">22160483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20525995">
<a name="20525995"></a>Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>N Engl J Med</i>. 2010;362(24):2260-2270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/20525995/pubmed" id="20525995" target="_blank">20525995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19195046">
<a name="19195046"></a>Khoury HJ, Guilhot F, Hughes TP, et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. <i>Cancer</i>. 2009;115(7):1381-1394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/19195046/pubmed" id="19195046" target="_blank">19195046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20131302">
<a name="20131302"></a>Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg Once Daily versus 70 mg Twice Daily in Patients With Ph-Positive Acute Lymphoblastic Leukemia Who Failed Imatinib: Results From a Phase 3 Study. <i>Am J Hematol</i>. 2010;85(3):164-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/20131302/pubmed" id="20131302" target="_blank">20131302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31584851">
<a name="31584851"></a>Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy outcomes in chronic myeloid leukemia: a single center experience. <i>J Glob Oncol</i>. 2019;5:1-11. doi:10.1200/JGO.18.00211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/31584851/pubmed" id="31584851" target="_blank">31584851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29315500">
<a name="29315500"></a>Montemurro M, Cioffi A, Dômont J, et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: a multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). <i>Cancer</i>. 2018;124(7):1449-1454. doi:10.1002/cncr.31234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/29315500/pubmed" id="29315500" target="_blank">29315500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26371140">
<a name="26371140"></a>Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. <i>J Clin Oncol</i>. 2015;33(35):4210-4218. doi:10.1200/JCO.2015.62.4718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/26371140/pubmed" id="26371140" target="_blank">26371140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients With cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17496201">
<a name="17496201"></a>Ottmann O, Dombret H, Martinelli G, et al. Dasatinib Induces Rapid Hematologic and Cytogenetic Responses in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Intolerance to Imatinib: Interim Results of a Phase 2 Study. <i>Blood</i>. 2007;110(7):2309-2315.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/17496201/pubmed" id="17496201" target="_blank">17496201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17761974">
<a name="17761974"></a>Quintás-Cardama A, Kantarjian H, O'brien S, et al. Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. <i>J Clin Oncol</i>. 2007;25(25):3908-3914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/17761974/pubmed" id="17761974" target="_blank">17761974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33826052">
<a name="33826052"></a>Rambhatla A, Strug MR, De Paredes JG, Cordoba Munoz MI, Thakur M. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. <i>J Assist Reprod Genet</i>. 2021;38(8):1897-1908. doi:10.1007/s10815-021-02181-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/33826052/pubmed" id="33826052" target="_blank">33826052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29046900">
<a name="29046900"></a>Ravandi F, Othus M, O'Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Adv</i>. 2016;1(3):250-259. doi:10.1182/bloodadvances.2016001495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/29046900/pubmed" id="29046900" target="_blank">29046900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27121472">
<a name="27121472"></a>Rousselot P, Coudé MM, Gokbuget N, et al; European Working Group on Adult ALL (EWALL) group. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. <i>Blood</i>. 2016;128(6):774-782. doi:10.1182/blood-2016-02-700153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/27121472/pubmed" id="27121472" target="_blank">27121472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20564086">
<a name="20564086"></a>Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-up in a Phase 3 Study: Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily. <i>Cancer</i>. 2010;116(16):3852-3861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/20564086/pubmed" id="20564086" target="_blank">20564086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29710216">
<a name="29710216"></a>Schuetze SM, Bolejack V, Thomas DG, et al. Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. <i>JAMA Oncol</i>. 2018;4(6):814-820. doi:10.1001/jamaoncol.2018.0601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/29710216/pubmed" id="29710216" target="_blank">29710216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24569263">
<a name="24569263"></a>Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. <i>Blood</i>. 2014;123(15):2317-2324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/24569263/pubmed" id="24569263" target="_blank">24569263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18541900">
<a name="18541900"></a>Shah NP, Kantarjian HM, Kim DW, et al. Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>J Clin Oncol</i>. 2008;26(19):3204-3212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/18541900/pubmed" id="18541900" target="_blank">18541900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20139391">
<a name="20139391"></a>Shah NP, Kim DW, Kantarjian H, et al. Potent, Transient Inhibition of BCR-ABL With Dasatinib 100 mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-Free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance, Suboptimal Response or Intolerance to Imatinib. <i>Haematologica</i>. 2010;95(2):232-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/20139391/pubmed" id="20139391" target="_blank">20139391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32734668">
<a name="32734668"></a>Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. <i>Br J Haematol</i>. 2020;191(2):171-193. doi:10.1111/bjh.16971<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/32734668/pubmed" id="32734668" target="_blank">32734668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sprycel.1">
<a name="Sprycel.1"></a>Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sprycel.2">
<a name="Sprycel.2"></a>Sprycel (dasatinib) [product monograph]. Montreal, Quebec, Canada: Bristol-Myers Squibb Canada; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33270732">
<a name="33270732"></a>Szakács Z, Hegyi PJ, Farkas N, et al. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a systematic review. <i>PLoS One</i>. 2020;15(12):e0243045. doi:10.1371/journal.pone.0243045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/33270732/pubmed" id="33270732" target="_blank">33270732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26951627">
<a name="26951627"></a>Yoon JH, Yhim HY, Kwak JY, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Ann Oncol</i>. 2016;27(6):1081-1088. doi:10.1093/annonc/mdw123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/26951627/pubmed" id="26951627" target="_blank">26951627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770225">
<a name="31770225"></a>Yu L, Huang X, Gale RP, Wang H, Jiang Q. Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Medicine (Baltimore)</i>. 2019;98(48):e18079. doi:10.1097/MD.0000000000018079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/31770225/pubmed" id="31770225" target="_blank">31770225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23715577">
<a name="23715577"></a>Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. <i>J Clin Oncol</i>. 2013;31(19):2460-2468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dasatinib-pediatric-drug-information/abstract-text/23715577/pubmed" id="23715577" target="_blank">23715577</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120511 Version 140.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
